Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses
Multivariable-adjusted hazard ratios for all-cause mortality reduced for one to 59, 60 to 149, 150 to 299, and ≥300 minutes/week
No evidence of effect modification seen in interaction analyses using polygenic score with seven polymorphisms, CYP1A2 rs762551 alone
Incidence of glenohumeral arthritis 1.7 per 100 person-years for posterior shoulder instability requiring surgical fixation
Proton pump inhibitors, beta-blockers, antimetabolites linked to infection with antibiotic-resistant bacteria
Intensive BP lowering after intracerebral hemorrhage linked to poorer outcomes in patients with decreased renal function
Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its two-dose vaccine
Likelihood of having complications higher for men than women and for those aged older than 60 years
As of May 15, 2021, coverage was lower for non-Hispanic Blacks and Hispanics versus Whites; higher for those at risk for severe COVID-19
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
Please login or register first to view this content.
Login Register